OR WAIT 15 SECS
Vectura will support the product from Phase I through to commercial launch.
Vectura, an inhalation contract development and manufacturing organization (CDMO), announced on Sept. 14, 2020 that it has partnered with Monash University’s Institute of Pharmaceutical Sciences (MIPS) for the development of an inhaled oxytocin delivered by a dry-powder inhaler to prevent postpartum hemorrhage (PPH) in childbirth.
Under the terms of the agreement, Vectura will support the product through commercialization by developing a single use device/formulation combination for Phase I evaluation followed by a technical transfer to a commercial manufacturer to advance to Phase III and commercial launch, a Vectura press release said.
“Reformulation of oxytocin to an inhaled dry powder has many advantages for this drug and application,” said Will Downie, CEO of Vectura, in the press release “It will be easy to administer for patients, and, being inhaled, will have a rapid onset of action. Working with Monash University and its partners, we look forward to providing Vectura’s deep expertise in this space to address this important global health issue, potentially preventing thousands of deaths each year.”
“Post-partum hemorrhage is a significant and challenging global health issue, so we are very excited to be working with Vectura on a low cost, heat stable, and non-invasive approach to deliver oxytocin, overcoming existing limitations of current injection products,” added Professor Michelle McIntosh, project lead at MIPS, in the press release.